IRADIMED CORPORATION— Sankey Diagram
Quarterly mode · period ending 2026-03-31 · SEC EDGAR
ComparingFY2026 (Q1+Q2+Q3+Q4) vs FY2025 (Q1+Q2+Q3+Q4)
Revenue
$86M
↑+14.8% +$11Mvs FY2025 (Q1+Q2+Q3+Q4)
Gross Profit
$66M
↑+14.7% +$8Mvs FY2025 (Q1+Q2+Q3+Q4)
Operating profit
$28M
↑+23.4% +$5Mvs FY2025 (Q1+Q2+Q3+Q4)
Net profit
$24M
↑+19.3% +$4Mvs FY2025 (Q1+Q2+Q3+Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2026 (Q1+Q2+Q3+Q4) | FY2025 (Q1+Q2+Q3+Q4) |
|---|---|---|
| Revenue | $86M | $75M |
| COGS | $20M | $17M |
| Gross Profit | $66M | $58M |
| R&D | $3M | $3M |
| SG&A | $0 | $0 |
| D&A | $1M | $786K |
| Other OpEx | $34M | $32M |
| Operating Income | $28M | $23M |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $28M | $23M |
| Tax | $4M | $3M |
| Net Income | $24M | $20M |
QuarterCharts · SEC EDGAR data · IRMD · Comparing FY2026 (Q1+Q2+Q3+Q4) vs FY2025 (Q1+Q2+Q3+Q4)